NCT02762162 Registry of Coronary Artery Ill Patients With Platelet Test Results
| NCT ID | NCT02762162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Action, France |
| Condition | Acute Coronary Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2007-01 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2007-01 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ONASSIST is a registry of coronary ill patients who have had a functional test measuring anti-platelet effect and/or a genetic profile of response to anti-platelet drugs.
Eligibility Criteria
Inclusion Criteria: * coronary disease * antiplatelets testing performed as part of usual care and / or gentic profile of antiplatelet response done Exclusion Criteria: * patient refusing to be part of the registry
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02762162 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Coronary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02762162 currently recruiting?
Yes, NCT02762162 is actively recruiting participants. Contact the research team at jean-philippe.collet@aphp.fr for enrollment information.
Where is the NCT02762162 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT02762162 clinical trial?
NCT02762162 is sponsored by Action, France. The trial plans to enroll 5,000 participants.